THE ROLE OF CORONAVIRUS INFECTION IN THE DEVELOPMENT OF DECOMPENSATION OF CARDIOVASCULAR DISEASES. THERAPY OPTIONS

DOI: https://doi.org/10.29296/25877305-2020-04-06
Download full text PDF
Issue: 
4
Year: 
2020

I. Zueva(1), MD; O. Plaksin(2) (1)Saint-Petersburg Medico-Social Institute (2)OOO «Samson-Med», Saint-Petersburg

The article presents current data on the impact of viral infection, including coronavirus SARS-CoV-2, on the development of decompensation of cardiovascular diseases. The use of cytochrome C is justified in patients with cardiovascular disease.
Keywords: 
cardiology
COVID-19
mitochondrial dysfunction
hypoxia
heart failure
cytochrome C

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Li J.-Y., You Z., Wang Q. et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future // Microbes Infect. – 2020; 22 (2): 80–5. DOI: 10.1016/j.micinf.2020.02.002.
  2. Guan W.J., Ni Z.Y., Zhong N.S. et al. Clinical characteristics of 2019 novel coronavirus infection in China // Med. Rxiv. – 2020; [Epub ahead of print]. https://doi.org/10.1101/2020.02.06.20020974.
  3. Yang Y., Lu Q.B., Liu M.J. et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China // Med. Rxiv. – 2020; [Epub ahead of print]. https://doi.org/10.1101/2020.02.10.20021675.
  4. Liu Y., Gayle A.A., Wilder-Smith A. et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus // J. Travel Med. – 2020; [Epub ahead of print]. DOI: 10.1093/jtm/taaa021.
  5. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. – 2020; 395: 497–506. DOI: 10.1016/S0140-6736(20)30183-5.
  6. Du R.H., Liang L.R., Yang C.Q. et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study // Eur. Respir. J. – 2020; Apr 8. DOI: 10.1183/13993003.00524-2020.
  7. Banerjee A., Kulcsar K., Misra V. et al. Bats and coronaviruses // Viruses. – 2019; 11 (1): 41. DOI:10.3390/v11010041.
  8. Yang D., Leibowitz J.L. The structure and functions of coronavirus genomic 3 and 5 ends // Virus Res. – 2015; 206: 120–33. DOI:10.1016/j.virusres.2015.02.025.
  9. Villar J., Zhang H., Slutsky A.S. Lung repair and regeneration in ARDS: role of PECAM1 and Wnt signaling // Chest. – 2019; 155: 587–94. DOI: 10.1016/j.chest.2018. 10.022.
  10. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin. Immunopathol. – 2017; 39: 529–39. DOI: 10.1007/s00281-017- 0629-x.
  11. Wan Y., Shang J., Graham R. et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decadelong structural studies of SARS // J. Virology. – 2020; 94 (7): pii: e00127-20. DOI: 10.1128/JVI.00127-20.
  12. Li X.C., Zhang J., Zhuo J.L. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases // Pharmacol. Res. – 2017; 125: 21–38. DOI: 10.1016/j.phrs.2017.06.005.
  13. Shljahto E.V., Konradi A.O., Arutjunov G P. i dr. Rukovodstvo po diagnostike i lecheniju boleznej sistemy krovoobraschenija v kontekste pandemii COVID-19 // Ross. kardiol. zhurn. – 2020; 25 (3): 3801 [Shlyakho E.V., Konradi A.O., Arutyunov G.P. et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic // Russian Journal of Cardiology. – 2020; 25 (3): 3801 (in Russ.)]. https://doi.org/10.15829/1560-4071-2020-3-3801
  14. Chesnokova N.P., Ponukalina E.V., Bizenkova M.N. Molekuljarno-kletochnye mehanizmy tsitotoksicheskogo dejstvija gipoksii // Nauchnoe obozrenie. Meditsinskie nauki. – 2017; 2: 60–3 [Chesnokova N.P., Ponukalina E.V., Bizenkova M.N. Molekuljarno-kletochnye mehanizmy citotoksicheskogo dejstvija gipoksii // Nauchnoe obozrenie. Medicinskie nauki. – 2017; 2: 60–3 (in Russ.)].
  15. Jessup M., Abraha W.T., Casey D.E. et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation // Circulation. – 2009; 119 (14): 1977–2016. DOI: 10.1161/CIRCULATIONAHA.109.192064.
  16. Hunt S.A., Abraham W.T. Chin M.H. et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society // Circulation. – 2005; 112 (12): e154–e235. DOI: 10.1161/CIRCULATIONAHA.105.167586.
  17. Dong N., Cai J., Zhou Y. et al. End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV // JACC: Heart Failure. – 2020; [Epub ahead of print]. https://doi.org/10.1016/j.jchf.2020.04.001.
  18. Bayeva M., Gheorghiade M., Ardehali H. Mitochondria as a therapeutic target in heart failure // J. Am. Coll. Cardiol. – 2013; 61: 599–610. DOI: 10.1016/j.jacc.2012.08.1021. Neely J.R., Liebermeister H., Battersby E.J. et al. Effect of pressure development on oxygen consumption by isolated rat heart // Am. J. Physiol. – 1967; 212: 804–14.
  19. Gheorghiade M., Larson C.J., Shah S.J. et al. Developing new treatments for heart failure: focus on the heart // Circ. Heart Fail. – 2016; 9(5): pii: e002727. DOI: 10.1161/CIRCHEARTFAILURE.115.002727.
  20. Boylston J.A., Sun J., Chen Y. et al. Characterization of the cardiac succinylome and its role in ischemia-reperfusion injury // J. Mol. Cell. Cardiol. – 2015; 88: 73–81. DOI: 10.1016/j.yjmcc.2015.09.005.
  21. Jenkins C.M., Yang K., Liu G. et al. Cytochromecis an oxidative stress-activated plasmalogenase that cleaves plasmenylcholine and plasmenylethanolamine at thesn-1 vinyl ether linkage // J. Biol. Chem. – 2018; 293 (22): 8693–709. DOI: 10.1074/jbc.ra117.001629.
  22. Vaduganathan M., Butler J., Pitt B. et al. Contemporary drug development in heart failure: call for hemodynamically neutral therapies // Circ. Heart Fail. – 2015; 8: 826–31. DOI: 10.1161/CIRCHEARTFAILURE.115.002271.
  23. Hanson K.P., Manojlov S.E., Polosova P.G. Vlijanie ekzogennogo tsitohroma S na okislitel'noe fosforilirovanie v nekotoryh organah zhivotnyh pri eksperimental'nom opuholevom roste i luchevoj bolezni. Mitohondrii / M.: Nauka, 1967; s. 68–71 [Hanson K.P., Manojlov S.E., Polosova P.G. Vlijanie jekzogennogo citohroma C na okislitel’noe fosforilirovanie v nekotoryh organah zhivotnyh pri jeksperimental’nom opuholevom roste i luchevoj bolezni. Mitohondrii / M.: Nauka, 1967; s. 68–71 (in Russ.)].
  24. Manojlov S.E., Nesterova L.A., Orlova I.A. i dr. Dejstvie tsitohroma S, galaktozy i uridintrifosfata na rost perevivaemyh opuholej // Vopr. onkol. – 1973; 19 (7): 62–5 [Manojlov S.E., Nesterova L.A., Orlova I.A. et al. Dejstvie citohroma S, galaktozy i uridintrifosfata na rost perevivaemyh opuholej // Vopr. onkologii. – 1973; 19 (7): 62–5 (in Russ.)].
  25. Slepneva L.V., Hanevich M.D., Zybina N.N. i dr. Tsitohrom S i ego klinicheskoe primenenie / L.: LNIIGiPK, 1990; s. 27–31 [Slepnjova L.V., Hanevich M.D., Zybina N.N. et al. Citohrom C i ego klinicheskoe primenenie / L.: LNIIGiPK, 1990; 27–31 (in Russ.)].
  26. Mhitarjan L.M. Mehanizm lechebnogo dejstvija tsitohroma S pri ostrom virusnom gepatite V // Eksperimental'naja i klinicheskaja meditsina. – 1987; 27 (6): 585–9 [Mhitarjan L.M. Mehanizm lechebnogo dejstvija citohroma C pri ostrom virusnom gepatite V // Eksperimental’naja i klinicheskaja medicina. – 1987; 27 (6): 585–9 (in Russ.)].
  27. Novikov V.S. Tsitohrom S i ego klinicheskoe primenenie / L.: LNIIGiPK, 1990; s. 52–7 [Novikov V.S. Citohrom C i ego klinicheskoe primenenie / L.: LNIIGiPK, 1990; s. 52–7 (in Russ.)].
  28. Semenova I.G., Balljuzek M.F., Tugusheva F.A. Effektivnost' terapii bol'nyh hronicheskoj serdechnoj nedostatochnost'ju i narushenijami ritma serdtsa preparatom tsitohrom C // Farmateka. – 2013; 10: 51–6 [Semenova I.G., Ballyuzek M.F., Tugusheva F.A. Efficacy of therapy of patients with chronic heart failure and cardiac arrhythmias using drug cytochrome C // Farmateka. – 2013; 10: 51–6 (in Russ.)].
  29. Jakovlev G.M., Ardashev V.N. Primenenie preparata Tsitohrom S dlja preventivnoj terapii oslozhnenij ostrogo infarkta miokarda // Remedium Privolzh'e. – 2009; 31–2 [Jakovlev G.M., Ardashev V.N. Primenenie preparata Citohrom C dlja preventivnoj terapii oslozhnenij ostrogo infarkta miokarda // Remedium Privolzh’e. – 2009; 31–2 (in Russ.)].